Pharmosa Biopharm Inc

Pharmosa Biopharm Inc exhibits a strong liquidity position, with cash and equivalents amounting to TWD 11,093,360,000, which is significantly higher than its total liabilities of TWD 216,428,000, resulting in a current ratio of 19.22. The company's price-to-book ratio of 2.32 suggests that the market values the company at a premium relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized. The company's market capitalization of TWD 4,765,738,467.6 reflects a relatively small market presence compared to industry peers. Profitability metrics for Pharmosa Biopharm Inc are negative, with a return on equity (ROE) of -2.58% and a return on assets (ROA) of -2.33%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at TWD -69,693,000, and the net income is also negative at TWD -52,920,000. The company's gross profit of TWD 10,000 is minimal compared to its revenue of TWD 75,000, suggesting high production costs or low pricing power. The company's revenue is concentrated in a single segment, as no additional segments are disclosed in the financial data. There is no information provided on geographic exposure, but the company is listed in Taiwan, which may indicate a regional focus. The lack of segment and geographic diversification could pose a concentration risk, as the company's performance is tied to a single business line and potentially a single market. Pharmosa Biopharm Inc's growth trajectory is uncertain, as the financial data does not provide forward-looking revenue projections or historical growth rates. The company's operating cash flow is negative at TWD -37,010,000, and its free cash flow is also negative at TWD -72,786,000. These figures suggest that the company is not generating sufficient cash from operations to fund its capital expenditures, which were TWD -27,866,000. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.06, indicating that it is primarily financed through equity. The risk assessment for Pharmosa Biopharm Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and high cash reserves provide a buffer against short-term liquidity pressures. However, the negative profitability metrics and lack of cash flow generation could pose long-term risks to the company's sustainability. The company's capital expenditures are funded through operating cash flow, which is negative, suggesting that the company may need to rely on external financing in the future. The company's dilution risk is currently low, but this could change if the company needs to raise additional capital to fund its operations or growth initiatives. Recent events and filings for Pharmosa Biopharm Inc do not indicate any significant changes in the company's financial position or strategic direction. The company's financial statements do not mention any recent acquisitions, partnerships, or regulatory changes that could impact its operations. The absence of recent events suggests that the company is in a stable but stagnant phase, with no clear catalysts for growth or transformation.